Oral analgesia in fixed-time interval administration versus spinal morphine for post-Cesarean pain: a randomised controlled trial

Enav Yefet1,2,3 · Salih Nassar1 · Julia Carmeli4 · Manal Massalha1,6 · Jamal Hasanein5 · Noah Zafran1,6 · Michael Rudin4 · Zohar Nachum1,6

Received: 9 January 2021 / Accepted: 17 August 2021 / Published online: 31 August 2021
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021

Abstract

Purpose To compare the efficacy of fixed-time-interval oral analgesia and spinal-morphine for management of post-Cesarean pain.

Methods In this open-label, parallel-group, randomized, controlled trial, 200 women due to undergo elective Caesarean section with spinal anaesthesia were enrolled between July 2015 and April 2016. Patients were randomly assigned to receive either spinal fentanyl followed by oral doses of tramadol, paracetamol, and diclofenac at predetermined regular intervals of 6 h for the first 48 h, and rescue treatment with percocet (oxycodone and paracetamol; oral analgesia group), or spinal morphine and rescue treatment with oral tramadol, paracetamol, and diclofenac (spinal-morphine group). The primary outcomes were pain intensity during the postoperative 48 h, measured on a 10-point numeric rating scale (NRS) and expressed as area under the curve (AUC), and the number of breakthrough events of moderate to severe pain (defined as NRS score ≥ 4).

Results The oral analgesia group compared to the spinal-morphine group had similar mean pain intensity (AUC (120 ± 35 versus 121 ± 31, respectively; p = 0.8) but more events of moderate-to-severe breakthrough pain (4.8 ± 2 versus 3.8 ± 1.7, respectively; p = 0.0002). Higher rates and longer durations of pruritus, nausea, and vomiting were reported among patients receiving spinal morphine, as compared with oral analgesia. Satisfaction scores were high in both groups (8.2 ± 2.4 versus 8.7 ± 1.8 in the oral analgesia and spinal morphine, respectively; p = 0.23).

Conclusions Both oral analgesia at fixed time intervals and spinal morphine are satisfactory methods for treating post-Caesarean pain.

Trial registration ClinicalTrials.gov Identifier: NCT02440399, date of registration: 07/05/2015. URL: https://clinicaltrials.gov/ct2/show/NCT02440399?term=enav+yefet&rank=7.

Keywords Post-Caesarean pain · Spinal morphine · Oral analgesia · Postpartum

Introduction

Post-Caesarean pain is an everyday challenge as Caesarean sections (CS) are one of the most prevalent laparotomies performed worldwide [1–3]. Inadequate maternal pain treatment has been suggested to impair maternal bonding, and decrease breastfeeding, infant care [4], and mobilisation, which may lead to thromboembolism [5, 6]. The importance of effective post-operative pain treatments is well acknowledged and a multimodal approach is taken by the obstetric team, anaesthesiologists and the nursing staff [7–11]. It is suggested that postoperative pain scores, measured using the visual analog scale (VAS), should be below 3, with patient satisfaction with their pain management [12, 13]. Practice guidelines recommend the use of spinal opioids to
treat post-Caesarean pain, because they have been shown to be more effective than intravenous opioids [8, 10]. Yet, a second-line treatment in cases, where spinal morphine cannot be used, has not been established. Such cases include CS under general anesthesia, contraindications for spinal morphine, such as allergy, or history of severe adverse reactions after previous use, e.g., severe pruritus, gastrointestinal adverse effects, urinary retention, and respiratory depression [10]. While respiratory depression is rare in the obstetric population [14], continuous monitoring for 12–24 h post-administration is recommended [15, 16].

In our previous study, we have shown that oral analgesia based on paracetamol, diclofenac, and tramadol given at fixed time intervals, was effective in treating post-Caesarean pain, as demonstrated by a mean pain score below 3 in the first 48 h following surgery, a low adverse effect profile and high satisfaction rate [7]. Oral analgesia was shown to be effective in other studies as well [17, 18]. Its advantages include ease of administration, need for less cumbersome equipment, low cost and suitability after general anesthesia. However, its effectiveness and safety have not been sufficiently compared to that of spinal morphine. The present study compared the efficacy of fixed time-interval oral analgesia for post-Caesarean pain to that of the more traditional treatment with spinal morphine.

**Methods**

**Design**

An open-label, parallel-group, randomised, controlled trial was conducted at Emek Medical Center, a university-affiliated hospital in Afula, Israel. This study was authorised by the local review board of Emek Medical Center on March 24, 2015 (ID of the approval EMC-28-15), was performed in accordance with relevant guidelines and regulations, and was registered on http://www.clinicaltrials.gov (NCT02440399, principal investigator E.Y, date of registration: May 07, 2015).

Participants provided written informed consent. Women who intended to undergo elective Cesarean delivery with spinal anesthesia between July 2015 and April 2016, were recruited to this study. Eligibility and all baseline measures were taken during the preoperative evaluation and before randomization. Women were approached 1 day before the surgery or in the morning, when the CS was scheduled to the afternoon. Exclusion criteria were chronic pain, substance abuse, known allergy to any drug used in the study, obstructive sleep apnea, body mass index (BMI) > 40 kg/m², periparative intravenous magnesium treatment, hypertension, renal failure, a history of severe post-operative nausea and vomiting and women who were designated to receive or who eventually underwent general anesthesia or who delivered vaginally.

Randomization of the groups was performed in a 1:1 ratio using a computer-generated randomization sequence; the randomization results were kept in sealed opaque envelopes, in a closed study box. The randomization sequence was concealed until intervention was assigned by physicians-investigators in this study.

**Interventions**

During recruitment, the study participants were instructed to report each time they suffered from pain or wanted additional analgesia regardless of the study group allocation. This instruction was repeated when they arrived to the maternity ward after surgery. In addition, women were asked to rank pain severity each time analgesia was administered or at least every 6 h by study nurses, who prior to the study had comprehensive guidance regarding the study protocol. Pain scores were recorded at rest for standardization. Pain assessment throughout the study was scored using the 10-point numeric rating scale (NRS), with whole integers (ranging from 0 (no pain) to 10 (worst pain)). The same group of anesthesiologists performed all the spinal anesthesia procedures.

Following randomization, patients were randomly allocated to one of two groups.

1. **Spinal morphine group**—received spinal anesthesia with 150 µg morphine and 10 mg bupivacaine (isobaric) before surgery. Fentanyl was not given during the spinal anesthesia due to reports that morphine might contradict the short-acting effect of fentanyl when administered together [19]. Patients did not receive additional analgesia unless requested in the following manner: In the recovery ward, patients who complained of pain intensity of ≥ 5 received intravenous 5 mg morphine. Repeated doses were given in 10-min intervals if the patient still reported NRS score ≥ 5. In the maternity ward, additional analgesia was given on demand or when reported NRS score for pain intensity was ≥ 4 (rescue treatments). In such cases, patients received two tablets of Zaldiar (each tablet contained paracetamol 325 mg and tramadol 37.5 mg) at minimal intervals of 6 h, and 100 mg diclofenac at minimal intervals of 12 h in the first 24 h from arrival to the maternity ward; an additional dose of diclofenac could be given after 48 h (Zaldiar and diclofenac were given simultaneously if the time frame allowed it).

2. **Oral analgesia group**—received spinal anesthesia with 25 µg fentanyl and 10 mg bupivacaine (isobaric) before surgery. Addition of fentanyl to intrathecal bupivacaine results in faster onset with improved peri-operative
anesthesia, without increasing the side effects [20]. In the recovery ward, patients who suffered from pain received the same protocol of IV morphine described above. Before transfer to the maternity ward, all patients received a tablet of Percocet (oxycodone 5 mg and paracetamol 325 mg). Once the patients arrived at the maternity ward, they received 100 mg intravenous tramadol hydrochloride (the only time an IV medication was used), a tablet of 500 mg paracetamol, and a tablet of 100 mg diclofenac. Six hours after patient arrival and every 6 h thereafter, patients received two tablets of Zaldiar. The patients also received a tablet of 100 mg diclofenac 12, 24, and 48 h after arrival. Patients were not woken for treatment. If additional analgesia was required, a tablet of perococet was given, as necessary, up to four times per day, at a minimal interval of 30 min (rescue treatment). The maximal allowed dose of paracetamol was 4 g per day. No woman in the study reached that dose. The oral analgesia protocol is the standard of care in our department.

In both study arms, pruritus was treated with promethazine. Nausea and vomiting were treated with granisetron and metoclopramide.

**Study outcomes**

The analysis focused on three main outcomes: (1) the analgesic effect of each treatment, (2) the safety profile and symptoms severity, and (3) patient satisfaction with the analgesia protocol. Two primary outcomes were addressed. The first was the sum of time-weighted NRS pain scores as an area under the curve (AUC) during the first 48 h post-CS for each participant. The curves were used to calculate the mean AUC for each cohort. An additional primary outcome was the number of events of breakthrough pain of moderate severity or higher, defined as NRS score ≥ 4 during the first 48 h from patient arrival at the maternity ward. This outcome was selected since both analgesia treatment arms were designed to prevent breakthrough pain. An NRS score of 4, which is considered moderate pain intensity, was chosen since it is the minimal score for which pain relievers can be offered by the nursing staff in our department. Breakthrough pain lasting up to 3 h was considered one event. After that, it was defined as a new event.

A structured questionnaire was used to evaluate the type, severity, and duration of adverse effects that may be related to the study medications. The events addressed included pruritus, nausea and vomiting, drowsiness, and an open question regarding any additional adverse effects, their duration and severity. Each adverse effect was scored on a scale ranging from 0 (not at all) to 10 (most severe). The questionnaires were distributed by investigators in this study (E.Y., Z.N., M.M., and S.N.) once from the third day post-surgery. Neonatal outcomes were also collected as described previously [7] and included altered consciousness, irritability, drowsiness, maximal neonatal bilirubin (mg/dL), need for phototherapy and adverse effects with possible relation to the pain medications or dehydration due to inadequate breastfeeding. The neonatal outcomes were documented by the nursing staff and physicians from the Department of Neonatology. The number of breastfeeds and supplemental formula used during the 5 days post-surgery (the standard hospitalization duration in our center) were also recorded.

Finally, patient satisfaction from each treatment protocol was evaluated using the questionnaire described above. Patients were asked if they would like the same treatment protocol in the future and whether they would recommend this treatment protocol to a friend. For each question, the patient gave a score from 1 (least satisfied/recommended) to 10 (most satisfied/recommended).

**Statistical analysis**

**Sample size**

As mentioned above, based on the available literature which demonstrated lower rates of breakthrough pain in the spinal morphine compared with oral analgesia [11], we hypothesized that spinal morphine will provide a superior analgesic effect.

In our previous study in which oral analgesia given at fixed time intervals was compared to oral analgesia administered on demand, the AUC of pain intensity during the 48-h post-surgery was around 140 ± 50 in the fixed time interval group [7]. Assuming a 20% lower AUC for those receiving spinal morphine (i.e. 115 ± 50), the sample size required 85 women for each group (5% 2-sided alpha, 90% power).

In addition, in the same study, a maximum of four rescue treatments for breakthrough pain events were required. Based on these data, the sample size of 85 women for each arm is sufficient to detect a 25% reduction in the average number of breakthrough pain events from 4 ± 2 to 3 ± 2 in the oral analgesia group vs. the spinal morphine group, respectively (5% 2-sided alpha, 90% power; 15% drop out was added). This sample size is sufficient to detect a mean difference of one event between the groups (± 2 standard deviations), which is the minimal possible difference.

Cohorts were compared at baseline using the Student t-test (or the Wilcoxon two sample test) for continuous variables and χ² (or Fisher’s exact test) for categorical variables. The number of women who suffered from moderate to severe breakthrough pain (NRS ≥ 4) was evaluated in blocks of 6 h each, from patient arrival at the maternity ward to 48 h afterwards. The statistical analyses were performed using SAS.
9.4 software (SAS Institute Inc., Cary, NC, USA.). Statistical significance was determined if \( p < 0.05 \).

The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request and subject to the directives of the institutional review board.

**Results**

Figure 1 describes the patient flow diagram. During the study period, 284 women underwent elective CS, including 12 who were not tested for eligibility since they
arrived on the weekend or were invited after cancelation of another patient. Of the 272 patients who were tested for eligibility, 253 women were eligible and 200 (80%) were randomised. After randomisation, eight patients in the spinal morphine group and five patients in the oral analgesia group were excluded from the study since they met exclusion criteria (Fig. 1).

Of the remaining patients, 89 women were randomised to receive spinal morphine. One woman received the oral analgesia protocol since the anesthesiologist was concerned that the patient was allergic to morphine (which was ruled out post-surgery). Her data were analysed together with the spinal morphine group according to the intention to treat principle. The oral analgesia was administered to 97 women who were included in the analysis.

There were 94 and 104 newborns in the spinal morphine group and oral analgesia groups, respectively (including 4 and 7 pairs of twins, respectively). All women were interested in breastfeeding as the primary nutrition method.

The baseline characteristics of the mothers and neonates were not different between the groups (Table 1).

### Analgesia effect

Maternal and neonatal outcomes are described in Table 2. The mean AUC for pain scores across the 48 h post-CS was similar between the cohorts (120 ± 35 versus 121 ± 31 in the oral analgesia and spinal morphine cohorts, respectively, \( p = 0.8 \)). In contrast, women in the spinal morphine group had fewer events of moderate to severe breakthrough pain (NRS pain \( \geq 4 \)) as compared with those receiving oral analgesia (3.8 ± 1.7 versus 4.8 ± 2.0, respectively; \( p = 0.0002 \)). In addition, fewer women in the spinal morphine as compared to the oral analgesia group reported NRS \( \geq 4 \) for pain between 6 and 18 h post-arrival.

### Table 1 Demographic and obstetric characteristics of mothers and neonates

| Characteristic                        | Oral analgesia          | Spinal morphine          |
|---------------------------------------|-------------------------|--------------------------|
| Maternal N=97                         |                         |                          |
| Maternal age (years)                  | 32.9 ± 5.0, 33 (29–37)  | 32.6 ± 5.3, 32 (30–37)   |
| BMI (kg/m²)                           | 25.6 ± 5.0, 24.5 (21.7–29.2) | 25.8 ± 5.5, 24.6 (21.8–28.4) |
| Delivery week                         | 38.6 ± 1.3, 38.6 (38.3–39.0) | 38.5 ± 0.8, 38.4 (38.1–39.0) |
| Preterm delivery (<37 weeks)          | 3 (3%)                  | 2 (2%)                   |
| Parity                                | 2.9 ± 1.4, 3 (2–3)      | 2.7 ± 1.0, 3 (2–3)       |
| Number of previous CSs                | 1.2 ± 1.0, 1 (0–2)      | 1.2 ± 1.0, 1 (0–2)       |
| Transverse corporal CS                | 2 (2%)                  | 0 (0%)                   |
| First CS                              | 29 (30%)                | 25 (28%)                 |
| Indications for CS                    |                         |                          |
| Previous CS                           | 68 (70%)                | 66 (73%)                 |
| Malpresentation                       | 10 (10%)                | 13 (14%)                 |
| Multiple gestation                    | 6 (6%)                  | 3 (3%)                   |
| Other                                 | 13 (13%)                | 8 (9%)                   |
| Multiple spinal attempts              | 4 (4%)                  | 4 (4%)                   |
| Duration of CS (h)                    | 1.11 ± 0.29, 1.03 [0.90–1.30] | 1.07 ± 0.32, 1.04 [0.85–1.24] |
| Morphine given at: PACU (mg)          | 1.4 ± 3.7, 0 (0–0)      | 2.1 ± 3.9, 0 (0–5)       |
| GDM                                   | 7 (7%)                  | 4 (4%)                   |
| Pre-GDM                               | 1 (1%)                  | 2 (2%)                   |
| Neonate N=104                         |                         |                          |
| Twins                                 | 14 (13%)                | 8 (9%)                   |
| Birth weight (g)                      | 3228 ± 501, 3215 (2880–3548) | 3167 ± 502, 3123 (2880–3465) |
| Apgar score 1 min after delivery      | 9.4 ± 0.6, 9 (9–10)     | 9.5 ± 0.6, 10 (9–10)     |
| Apgar score 5 min after delivery      | 9.98 ± 0.1, 10 (10–10)  | 9.98 ± 0.2, 10 (10–10)  |
| Arterial cord pH                      | 7.30 ± 0.05, 7.30 (7.28–7.33) | 7.29 ± 0.05, 7.29 (7.26–7.31) |
| Arterial cord pH < 7.1                | 1 (1%)                  | 0 (0%)                   |
| Admission to the NICU                 | 4 (4%)                  | 5 (5%)                   |

Values are given as mean ± standard deviation, median (IQR) or number (percent)

BMI body mass index, CS Cesarean section, GDM gestational diabetes mellitus, NICU neonatal intensive care unit, PACU post-anesthesia care unit
to the maternity ward (Fig. 2; \( p < 0.05 \)). At the remaining times, pain scores were not statistically different between the groups (Fig. 2). There was no difference in the number of events of severe breakthrough pain (NRS \( \geq 6 \)) between the spinal morphine and oral analgesia cohorts (Table 2).

### Table 2 Maternal and neonatal outcomes

| Outcome                                           | Oral analgesia | Spinal morphine | \( p \) value |
|---------------------------------------------------|----------------|-----------------|--------------|
| Maternal                                          |                |                 |              |
| Mean AUC for pain scores across first 48 h post-CS| 120 ± 35, 119 (98–144) | 121 ± 31, 120 (101–139) | 0.80         |
| No. events per woman of moderate and severe pain (NRS pain \( \geq 4 \)) | 4.8 ± 2.0, 5 (4–6) | 3.8 ± 1.7, 3 (3–5) | 0.0002       |
| No. events per woman of severe pain (NRS pain \( \geq 6 \)) | 3.0 ± 1.9, 3 (1–4) | 2.7 ± 1.5, 3 (2–4) | 0.45         |
| No. of times that analgesic agents were given during first 48 h | 5.4 ± 1.8, 5 (4–7) | 3.3 ± 1.8, 3 (3–5) | <0.0001      |
| No. of times that analgesic agents were given beyond 48 h | 2.7 ± 1.9, 2 (1–4) | 1.9 ± 1.7, 1 (1–3) | 0.002        |
| Satisfaction score from the analgesic treatment | 8.2 ± 2.4, 9 (8–10) | 8.7 ± 1.8, 9 (8–10) | 0.23         |
| Requesting for the same analgesic protocol in the next CS score\( ^a \) | 8.3 ± 2.8, 10 (8–10) | 8.9 ± 2.3, 10 (9–10) | 0.20         |
| Recommending the same analgesic treatment to a friend undergoing CS score\( ^a \) | 8.4 ± 2.8, 10 (8–10) | 8.9 ± 2.3, 10 (9–10) | 0.26         |
| Pruritus (severity score)\( ^{**} \) | 2.4 ± 3.1, 0 (0–4) | 4.2 ± 3.8, 4 (0–7) | 0.0007       |
| Pruritus—severity score \( \geq 5 \) (number of patients) | 24 (25%) | 43 (48%) | 0.001       |
| Pruritus (h) | 6.0 ± 13.2, 0 (0–4) | 19.0 ± 19.4, 12 (0–36] | <0.0001     |
| Nausea (severity score)\( ^b \) | 0.7 ± 1.9, 0 (0–0) | 1.6 ± 3.0, 0 (0–3) | 0.025        |
| Nausea—severity score \( \geq 5 \) (number of patients) | 7 (7%) | 15 (17%) | 0.045       |
| Nausea (h) | 1.4 ± 5.6, 0 (0–0) | 4.1 ± 10.9, 0 (0–1) | 0.04         |
| Vomiting (h) | 0.3 ± 1.5, 0 (0–0) | 3.7 ± 9.4, 0 (0–0) | 0.001        |
| Drowsiness (severity score)\( ^b \) | 1.3 ± 2.8, 0 (0–0) | 1.1 ± 2.6, 0 (0–0) | 0.40         |
| Drowsiness (h) | 6.7 ± 15.9, 0 (0–0) | 4.4 ± 12.7, 0 (0–0) | 0.35         |
| Adverse effects that bothered the patient (score)\( ^b \) | 2.2 ± 3.1, 0 (0–4) | 3.6 ± 3.6, 3 (0–6) | 0.006        |
| Adverse effects that bothered the patient-severity score \( \geq 5 \) | 24 (25%) | 37 (41%) | 0.02       |
| No. patients who reported that the severity of adverse effects justified treatment avoidance\( ^b \) | 6 (6%) | 11 (12%) | 0.14        |
| Total number of hospitalization days | 3.8 ± 0.7, 3.8 (3.1–4.1) | 3.8 ± 0.8, 3.8 (3.1–4.1) | 1          |
| Neonate                                           |                |                 |              |
| Maximal bilirubin (mg/dL)\( ^c \) | 8.0 ± 2.9, 8.5 (6.4–10.2) | 8.2 ± 3.0, 8.7 (6.5–10.1) | 0.65        |
| Phototherapy (number of neonates)\( ^d \) | 8 (8%) | 4 (4%) | 0.3         |
| Jaundice (number of neonates)\( ^d \) | 17 (16%) | 18 (19%) | 0.6        |
| Breastfeeding (number of times)\( ^d \) | 17.0 ± 8.7, 17 (12–23) | 15.5 ± 9.9, 17 (8–22) | 0.45        |
| Use of supplemental formula (number of times)\( ^d \) | 13.8 ± 11.3, 10 (5–21) | 14.1 ± 9.1, 12.5 (7–20) | 0.39        |
| Change in neonatal weight at the time of discharge (g) | \(-204 ± 103, -201 (-261 to -155)\) | \(-201 ± 79, -205 (-248 to 155)\) | 0.82        |
| Respiratory distress | 3 (3%) | 2 (2%) | 1          |

Values are given as mean ± standard deviation, median (IQR) or number (percent). Satisfaction scores and adverse events profile were evaluated by structured questionnaires (one participant in the spinal morphine group did not answer the questionnaire).

\( AUC \) area under the curve, \( CS \) Caesarean section, \( NRS \) numeric rating scale

\( ^a \) These parameters were evaluated using a scale from 1 (not at all) to 10 (highly satisfied/recommended)

\( ^b \) Severity score for adverse effect was evaluated using a scale from 0 (not at all) to 10 (most severe)

\( ^c \) Refers to 5 days of hospitalisation

### Adverse effect profile

Data regarding the rate, severity, and duration of adverse effects related to the study medications are presented in Table 2. The spinal morphine group had a higher rate and
longer duration of pruritus, nausea, and vomiting compared with the oral analgesia group. Additionally, in each cohort, six women (6%) reported dizziness \( (p=0.9) \). In the spinal morphine group, one woman had a rash. In the oral analgesia group, two women reported headache, one woman reported leg weakness, one reported on sweats, and one had a case of burning sensation in the eyes.

The neonatal outcomes were comparable between the cohorts (Table 2). Five cases of respiratory distress were reported. In the spinal morphine group, one neonate, born in gestational week 38, needed non-invasive ventilator support. Another baby, born in gestational week 37, choked after feeding with supplemental formula. In the oral analgesia group, two babies had respiratory distress related to prematurity (gestational weeks 30 and 34) and one baby, born in gestational week 38, needed non-invasive oxygen support. Following meticulous investigation by the pediatricians, none of those events were considered related to the study medications.

**Patient satisfaction from the analgesia protocols**

Patient scores for satisfaction from the analgesia protocols, and willingness to undergo the same treatment protocol in the next surgery and to recommend it to a friend were high and not statistically different between the cohorts (Table 2).

**Discussion**

The present study compared the efficacy of oral analgesia administered at fixed time intervals for the treatment of post-Cesarean pain in the first 48 h following CS to that of spinal morphine. While the mean pain intensity was not different between the cohorts, spinal morphine was more effective in preventing breakthrough pain during the first 6–18 h, but was associated with a higher rate of adverse effects and satisfaction scores comparable with those for oral analgesia.

Both spinal opioids and oral analgesia protocols have been shown to be effective in treating post-operative pain [9, 10, 17, 18, 21–24]. However, a direct comparison of the two, in order to evaluate if oral analgesia could be an alternative for spinal morphine, has never been adequately studied. One study with a small sample size compared oral analgesia to spinal morphine. In the study, 120 women received either sustained-release oral oxycodone 20 mg in the recovery room, followed by immediate-release oxycodone 10 mg 6-hourly for the first 24 h, or intrathecal morphine 100 µg at the time of spinal anesthesia. All women received postoperative paracetamol and 8-hourly diclofenac, starting at least 12 h postoperatively.
Oxycodone and tramadol were used for rescue treatment. The AUC for pain scores across the first 24 h did not differ significantly between groups. Pruritus was reported less frequently in the oral analgesia group, but satisfaction scores were also lower in this group [11]. Higher intensity of worst pain in the 24 post-operative hours was suggested to contribute to these inferior satisfaction scores, underscoring the importance of addressing breakthrough pain as a primary endpoint. The study was limited by its small sample size, breakthrough pain being only a secondary outcome and the fact that oral analgesia was probably not given sufficiently, as suggested by the fact that 82% of the women in the oral analgesia group requested additional analgesia [11]. Breakthrough pain is a major challenge during postoperative care. In a previous study, around 68% women undergoing major gynecologic surgery had breakthrough pain requiring rescue analgesia within 48 h postoperatively, even though different continuous analgesia methods were given [25]. In the current study, the number of women with NRS ≥ 4 between 24 and 48 h after arrival to the maternity ward was comparable between the cohorts, although the spinal morphine group did not receive any regular analgesia. This may be explained by the long-term effect of morphine, persisting longer than 24 hours, the low rate of breakthrough pain events in both cohorts for demonstrating any statistically significant difference, and that woman in the spinal morphine group received analgesia following demand that was sufficient to alleviate pain.

In our study, more women in the spinal morphine cohort reported pruritus that was difficult to manage. The exact mechanism of neuraxial opioid-induced pruritus is unclear [26] and its rate seems to be higher, affecting > 80% of postpartum patients even on administration of a low dose of 100 μg intrathecal morphine [26]. Interaction of estrogen with opioid receptors was suggested to underlie the phenomenon [27, 28]. Our findings are also consistent with previous reports of shorter duration of pruritus following fentanyl treatment, as compared to pruritus invoked by spinal morphine [11, 26, 29].

The oral analgesia protocol had a better safety profile than the spinal morphine protocol, but was less effective in providing pain relief, particularly during the 6–18 h following patient arrival at the maternity ward. The fact that women were not woken for analgesia administrations may have contributed to that. Multiple administrations at different times for each patient also complicated this protocol. A solution which was implemented in our department was fixed-interval dosing, administered when the patients were expected to be awake (e.g., at 6:00, 12:00, 18:00, and 24:00). Another way to simplify the protocol is to administer 400 mg ibuprofen every 6 h, together with Zaldiar instead of diclofenac. Future studies should examine whether a combination of spinal morphine and oral analgesia at fixed time intervals is superior to each method individually.

The strengths of this study were the high recruitment rate, its prospective randomised controlled design and the use of multiple endpoints for evaluating each treatment protocol. The limitations of this study included its single-center nature, the focus on short-term outcomes, and the open-label treatment administration, which is subject to bias. The types and nature of the questions in the structured questionnaire and the fact that this questionnaire was not validated may have also influenced the results, as previously suggested [30], yet, since both groups received the same questionnaire, this possible limitation was minimised. An additional limitation lay in the fact that the anaesthetic and post-analgesic regimens used in this study may not be in line with those used in other institutions. Nevertheless, the principle of using oral analgesia at fixed time intervals remains valid, regardless of the specific medications.

In conclusion, both spinal morphine and oral analgesia were shown to effectively prevent and alleviate post-CS pain, with high and comparable satisfaction scores. Spinal morphine was slightly better for pain prevention, however, at a cost of an increased adverse effect rate. Oral analgesia at fixed time intervals is a good alternative for spinal morphine in cases of general anaesthesia, contraindications for spinal morphine such as allergy, or substantial adverse effects.

Author contributions  

This study was not funded by any organization.

Declarations  

Conflict of interest  All the authors declare that they have no conflict of interest.

Ethical approval  All procedures performed in studies involving human participants were in accordance with the ethical standards of the Emek Medical Center institutional review board and with the 1964 Helsinki declaration and its later amendments.

Informed consent  All patients gave a written informed consent form.

References  

1. MacDorman MF, Menacker F, Declercq E (2008) Cesarean birth in the United States: epidemiology, trends, and outcomes. Clin Perinatol 35(2):293–307, v
2. Sebastian YV, Womack L, Vamos CA, Louis JM, Olanye F, Car- 
gan T et al (2016) Hospital variation in Cesarean rates: contribu- 
tion of individual and hospital factors in Florida. Am J Obstet 
Gynecol 214(1):123.e1–123.e18
3. Boyle A, Reddy UM (2012) Epidemiology of Cesarean delivery: 
the scope of the problem. Semin Perinatol 36(5):308–314
4. Karlstrom A, Engstrom-Olofsson R, Norbergh KG, Sjoling M, 
Hildingsson I (2007) Postoperative pain after Cesarean birth 
affects breastfeeding and infant care. J Obstet Gynecol Neonatal 
Nurs 36(5):430–440
5. Leung AY (2004) Postoperative pain management in obstet-
ric anesthesia—new challenges and solutions. J Clin Anesth 
16(1):57–65
6. Toglia MR, Nolan TE (1997) Venous thromboembolism during 
pregnancy: a current review of diagnosis and management. Obstet 
Gynecol Surv 52(1):60–72
7. Yefet E, Taha H, Salim R, Hasanen J, Carmeli Y, Schwartz N et al 
(2017) Fixed time interval compared with on-demand oral anal-
gesia protocols for post-caesarean pain: a randomised controlled 
trial. BJOG 124(7):1067–1070
8. Practice Guidelines for Obstetric Anesthesia (2016) An updated 
report by the American Society of Anesthesiologists Task Force 
on Obstetric Anesthesia and the Society for Obstetric Anesthesia 
and Perinatology. Anesthesiology 124(2):270–300
9. Jakobi P, Weiner Z, Solt I, Alpert I, Itskovitz-Eldor J, Zimmer EZ 
(2000) Oral analgesia in the treatment of post-Cesarean pain. Eur 
J Obstet Gynec Reprod Biol 93(1):61–64
10. Gadsden J, Hart S, Santos AC (2005) Post-Cesarean delivery anal-
gesia. Anesth Analg 101(S Suppl):S62–S69
11. McDonnell NJ, Paech MJ, Browning RM, Nathan EA (2010) A 
randomised comparison of regular oral oxycodone and intrathe-
clar morphine for post-Caesarean analgesia. Int J Obstet Gynaecol 
19(1):16–23
12. National Pharmaceutical Council, Inc (2001) Pain: current un-
derstanding of assessment, management, and treatments [mono-
graph]. Joint Commission on Accreditation of Healthcare Organiza-
tions. https://www.npcnow.org/resources/pain-current-under-
standing-assessment-management-and-treatments
13. Pickering EH (2006) A pain relief after Caesarean section. In: 
Kinsella M (ed) Raising the standard: a compendium of audit reci-
pes, 2nd edn. Royal College of Anaesthetists, London, pp 168–169
14. Abouleish E, Rawal N, Rashad MN (1991) The addition of 
0.2 mg subarachnoid morphine to hyperbaric bupivacaine for 
Cesarean delivery: a prospective study of 856 cases. Reg Anesth 
16(3):137–140
15. Practice Guidelines for the Prevention (2016) Detection, and 
management of respiratory depression associated with neuraxial 
administration of neuraxial morphine for Cesarean delivery anal-
gesia. Anesth Analg 129(2):458–474
16. Zhong TD, Liu Q, Zhao JN, Wang HW, Konstantatos A (2014) A 
randomized trial to compare pain control using oral analgesia 
with epidural analgesia after Cesarean section following combined 
spinal-epidural anesthesia. Genet Mol Res 13(3):7086–7093
17. Lowder JL, Shakkelford DP, Holbert D, Beste TM (2003) A rand-
omized, controlled trial to compare ketorolac tromethamine versus 
placebo after Cesarean section to reduce pain and narcotic usage. 
Am J Obstet Gynecol 189(6):1559–1562
18. Weigl W, Bierlylo A, Wielgus M, Kozomien-Wiczynska S, Kolacz 
M, Dabrowski MJ (2017) Perioperative analgesia after intrathecal 
fentanyl and morphine or morphine alone for Cesarean section: a 
randomized controlled study. Medicine (Baltim) 96(48):e8892
19. Bano F, Sabbar S, Zafar S, Rafeeq N, Iqbal MN, Haidar S et al 
(2006) Intrathecal fentanyl as adjunct to hyperbaric bupivacaine 
in spinal anesthesia for caesarean section. J Coll Physicians Surg 
Pak 16(2):87–90
20. Dieterich M, Muller-Jordan K, Stubert J, Kuntz G, Wagner K, 
Gerber B (2013) Pain management after Cesarean: a randomized 
controlled trial of oxycodone versus intravenous piritramide. Arch 
Gynecol Obstet 286(4):859–865
21. Davis KM, Esposito MA, Meyer BA (2006) Oral analgesia com-
pared with intravenous patient-controlled analgesia for pain after 
Cesarean delivery: a randomized controlled trial. Am J Obstet 
Gynecol 194(4):967–971
22. Sammour RN, Ohel G, Cohen M, Gonen R (2011) Oral naproxen 
versus oral tramadol for analgesia after Cesarean delivery. Int J 
Gynaecol Obstet 113(2):144–147
23. Dalling B, Mirza F, Flood P (2017) Patient choice compared with 
no choice of intrathecal morphine dose for caesarean anal-
gesa: a randomized clinical trial. Br J Anaeth 118(5):762–771
24. Ismail S, Siddiqui AS, Rehman A (2018) Postoperative pain man-
agement practices and their effectiveness after major gynecologi-
cal surgery: an observational study in a tertiary care hospital. J 
Anaesthesiol Clin Pharmacol 34(4):478–484
25. Kumar K, Singh SI (2013) Neuraxial opioid-induced pruritus: an 
update. J Anaesthesiol Clin Pharmacol 29(3):303–307
26. Krajnik M, Zylcz Z (2001) Understanding pruritus in systemic 
disease. J Pain Symptom Manag 21(2):151–168
27. LaBella FS, Kim RS, Templeton J (1978) Opiate recep-
tor binding activity of 17-alpha estrogenic steroids. Life Sci 
23(17–18):1797–1804
28. Carvalho B, Mirza F, Flood P (2017) Patient choice compared with 
no choice of intrathecal morphine dose for caesarean anal-
gesa: a randomized clinical trial. Br J Anaeth 118(5):762–771
29. Ismail S, Siddiqui AS, Rehman A (2018) Postoperative pain man-
agement practices and their effectiveness after major gynecologi-
cal surgery: an observational study in a tertiary care hospital. J 
Anaesthesiol Clin Pharmacol 34(4):478–484
30. Kumar K, Singh SI (2013) Neuraxial opioid-induced pruritus: an 
update. J Anaesthesiol Clin Pharmacol 29(3):303–307
31. Krajnik M, Zylcz Z (2001) Understanding pruritus in systemic 
disease. J Pain Symptom Manag 21(2):151–168
32. LaBella FS, Kim RS, Templeton J (1978) Opiate recep-
tor binding activity of 17-alpha estrogenic steroids. Life Sci 
23(17–18):1797–1804
33. Reich A, Szepietowski JC (2010) Opioid-induced pruritus: an 
update. Clin Exp Dermatol 35(1):2–6
34. Chooh CS, White AM, Tan SG, Dowling K, Cyna AM (2013) Pain 
vs comfort scores after Cesarean section: a randomized trial. Br 
J Anaesth 110(5):780–787

Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affilia-
tions.